IJCS | Volume 33, Nº4, July and August 2020

399 monitoring treatment response and progression over time. Those modalities demonstrate distinct distribution and patterns of the disease at different stages, such as perfusion defects due to fibrosis, FDG uptake or elevation of T2 signal caused by inflammation as well as impairment of the ventricular function. Prospective randomized controlled trials as CHASM CS-RCT are needed to validate not only the role of imaging in diagnosis but also in order to assess therapy management to guide the best treatment for each individual, taking into consideration not only the response but also patient’s quality of life. Author contributions Conception and design of the research: Wiefels C. Writing of the manuscript: Wiefels C, Lamai O, Kandolin R, Birnie D, Leung, E, Mesquita CT, Beanlands R. Critical revision of themanuscript for intellectual content: Wiefels C, Lamai O, Kandolin R, Birnie D, Leung, E, Mesquita CT, Beanlands R. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This article is part of the thesis of Doctoral submitted by Christiane Wiefels, from Universidade Federal Fluminense . Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. 1. Boeck C. Multiple benign sarkoid of the skin. Arch Dermatol. 1982;118(10):710-20. 2. Valeyre D, PrasseA, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383(9923):1155-67. 3. Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA. Epidemiology of sarcoidosis in a prospective cohort study of U.S. Women. Ann Am Thorac Soc. 2016;13(1):67-71. 4. Erdal BS, Clymer BD, Yildiz VO, Julian MW, Crouser ED. Unexpectedly high prevalence of sarcoidosis in a representative U.S. Metropolitan population. Respir Med. 2012;106(6):893-9. 5. Chareonthaitawee P, Blankstein R. Reply: Role of 18 F-FDG PET/CT in cardiac sarcoid detection and therapymonitoring:Addition to the expert consensus. J Nucl Med. 2019; 60: 293–4. 6. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: Epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624–32. 7. Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26-31. 8. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10):1885-9. 9. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. Epidemiology and clinical picture. Sarcoidosis. 1990;7(1):50-7. 10. Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234-41. 11. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013;18(6):733–46. 12. Greulich S, Deluigi CC, Gloekler S, WahlA, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501-11. 13. Dubrey SW, Falk RH. Diagnosis andManagement of Cardiac Sarcoidosis. Prog Cardiovasc Dis. 2010;52(4):336-46. 14. Zhou Y, Faber TL, Patel Z, Folks RD, Cheung AA, Garcia E V, et al. An automatic alignment tool to improve repeatability of left ventricular function and dyssynchrony parameters in serial gated myocardial perfusion SPECT studies. Nucl Med Commun. 2013;34(2):124-9. 15. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58(6):1204-11. 16. Tavora F, Cresswell N, Li L, Ripple M, Solomon C, BurkeA. Comparison of Necropsy Findings in Patients With Sarcoidosis Dying Suddenly from Cardiac Sarcoidosis Versus Dying Suddenly from Other Causes. Am J Cardiol. 2009;104(4):571-7. 17. UemuraA, Morimoto SI, Hiramitsu S, Kato Y, Ito T, HishidaH. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. Am Heart J. 1999;138(2):299-302. 18. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study on fatal myocardial sarcoidosis.AnnNYAcad Sci. 1976;278(1):455-69. 19. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58(6):1204-11. 20. Tavora F, Cresswell N, Li L, Ripple M, Solomon C, BurkeA. Comparison of Necropsy Findings in Patients With Sarcoidosis Dying Suddenly from Cardiac Sarcoidosis Versus Dying Suddenly from Other Causes. Am J Cardiol. 2009;104(4):571-7. 21. Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. Am J Med. 1977;63(1):86–108. 22. Wyplosz B, Marijon E, Dougados J, Pouchot J. Sarcoidosis: An unusual cause of acute pericarditis. Acta Cardiol. 2010;65(1):83-4. 23. Yazaki Y, Isobe M, Hiroe M, Morimoto SI, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiacsarcoidosistreatedwithprednisone.AmJCardiol.2001;88(9):1006-10. References Wiefels et al. 18F-FDG PET/CT and cardiac sarcoidosis Int J Cardiovasc Sci. 2020; 33(4):389-400 Review Article